Sign in
Taking peoplePhase 1

Testing DO-2 in adults with advanced or hard-to-treat solid tumours

Tests DO-2, a MET inhibitor, in adults with advanced solid tumours.

Key facts

Who runs it
Deuteroncology
Where
Gdansk, Lodz, Lublin, and Wroc?aw, PolandSee the 4 sitesAlso in 4 other countries, 17 sites
Registry title
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
Status
Recruiting
Phase
Phase 1
People taking part
138 people, planned
Started
13 Apr 2023
Expected to end
1 Jun 2027
Type of study
Interventional
Record updated
12 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or hard-to-treat solid tumours (Part 1), and adults with advanced non-small cell lung cancer that cannot be removed by surgery or has spread (Part 2).

Age
18 years or older
Sex
All sexes can join
Disease stage
Part 1: advanced or refractory solid tumours. Part 2: locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC).

Main reasons for not taking part

  • Healthy volunteers cannot join

Where in Poland

Also in 4 other countries, 17 sites

  • Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych FazGdansk, PolandNot yet recruiting
  • Instytut Centrum Zdrowia Matki PolkiLodz, PolandNot yet recruiting
  • Uniwersytecki Szpital Kliniczny nr 4 w LublinieLublin, PolandNot yet recruiting
  • Dolnoslaskie Centrum Onkologii, Pulmonologii i HematologiiWroc?aw, PolandNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Testing DO-2 in adults with advanced or hard-to-treat solid tumoursGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
12 August 2026